Highlights•Studies have shown that high PTH was associated with NAFLD/NASH, although the results from existing studies are inconsistent.•Using systematic review, 10 and 4 studies reported the association of PTH with NAFLD and NASH, respectively.•The meta-analysis suggested that high PTH can be a marker of NAFLD.•The meta-analysis also revealed that high PTH tended to be associated… Continue reading High #parathyroid hormone level as a marker of non-alcoholic #fatty #liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis
Category: Hepatology
Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction
Highlights•Diet-induced NAFLD and associated systemic alterations result in behavioural changes and low-grade brain tissue hypoxia.•Brain hypoxia is likely linked to the induced low-grade brain inflammation, as well as cerebrovascular, glial, and metabolic alterations.•Mct1 haploinsufficient mice are protected from NAFLD and detrimental cerebral alterations.•MCT1 is a potential novel therapeutic target for preventing and/or treating NAFLD and the… Continue reading Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction
Elevated C-reactive protein mediates the liver-brain axis: a preliminary study
BackgroundChronic liver diseases of all etiologies exist along a spectrum with varying degrees of hepatic fibrosis. Despite accumulating evidence implying associations between liver fibrosis and cognitive functioning, there is limited research exploring the underlying neurobiological factors and the possible mediating role of inflammation on the liver-brain axis.MethodsUsing data from the UK Biobank, we examined the cross-sectional association… Continue reading Elevated C-reactive protein mediates the liver-brain axis: a preliminary study
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
BACKGROUNDPegozafermin is a long-acting glycopegylated (pegylated with the use of site-specific glycosyltransferases) fibroblast growth factor 21 (FGF21) analogue in development for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. The efficacy and safety of pegozafermin in patients with biopsy-proven noncirrhotic NASH are not well established.METHODSIn this phase 2b, multicenter, double-blind, 24-week, randomized, placebo-controlled trial,… Continue reading Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis
BackgroundThe prevalence of hypertension (HTN) is higher in patients with non-alcoholic fatty liver disease (NAFLD). Inflammation is the key link between HTN and NAFLD. Systemic inflammation can be dramatically increased by inflammatory diet intake. However, whether controlling the inflammatory diet intake in NAFLD patients could affect the occurrence of HTN still remains unknown. Our aim… Continue reading Association between dietary inflammation index and hypertension in participants with different degrees of liver steatosis
Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Fibrosis is a key determinant of clinical outcomes in nonalcoholic fatty liver disease (NAFLD), but time-dependent risk of mortality has not been reported in previous meta-analyses. We performed an updated time-to-event meta-analysis to provide robust estimates for all-cause and liver-related mortality in biopsy-confirmed NAFLD with comparisons between fibrosis stages.MethodsMedline and Embase databases were searched to… Continue reading Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver DiseaseThe TREATY-FLD Randomized Clinical Trial
Importance The efficacy and safety of time-restricted eating (TRE) on nonalcoholic fatty liver disease (NAFLD) remain uncertain.Objective To compare the effects of TRE vs daily calorie restriction (DCR) on intrahepatic triglyceride (IHTG) content and metabolic risk factors among patients with obesity and NAFLD.Design, Setting, and Participants This 12-month randomized clinical trial including participants with obesity… Continue reading Effects of Time-Restricted Eating on Nonalcoholic Fatty Liver DiseaseThe TREATY-FLD Randomized Clinical Trial
Increased Intake of Both Caffeine and Non-Caffeine Coffee Components Is Associated with Reduced NAFLD Severity in Subjects with Type 2 Diabetes
Coffee may protect against non-alcoholic fatty liver disease (NAFLD), but the roles of the caffeine and non-caffeine components are unclear. Coffee intake by 156 overweight subjects (87% with Type-2-Diabetes, T2D) was assessed via a questionnaire, with 98 subjects (all T2D) also providing a 24 h urine sample for quantification of coffee metabolites by LC–MS/MS. NAFLD… Continue reading Increased Intake of Both Caffeine and Non-Caffeine Coffee Components Is Associated with Reduced NAFLD Severity in Subjects with Type 2 Diabetes
Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial
Management of nonalcoholic steatohepatitis (NASH) is a currently unmet clinical need. Digital therapeutics (DTx) is an emerging class of medicine that delivers evidence-based therapeutic interventions. The current study was aimed at investigating the efficacy of DTx in patients with NASH.METHODS: We conducted a multicenter, single-arm, 48-week trial in 20 patients with biopsy-confirmed NASH. All patients received… Continue reading Impact of a novel digital therapeutics system on nonalcoholic steatohepatitis: the NASH App clinical trial
2 Medical News 